Aktuellt
SENASTE
Redeye revisits the Initiator Pharma equity story following the company’s continued clinical advancements and recent capital raise. As we continue to see a compelling case rooted in an exciting and growing pipeline, bolstered by strong management and a solid ownership base, we slightly raise our Base Case.
LÄS MER
